Literature DB >> 20048679

T-cell dysfunction in HIV-1-infected patients with impaired recovery of CD4 cells despite suppression of viral replication.

Christian Erikstrup1, Gitte Kronborg, Nicolai Lohse, Sisse Rye Ostrowski, Jan Gerstoft, Henrik Ullum.   

Abstract

INTRODUCTION: CD4 T-cell recovery is impeded in some HIVinfected patients despite successful combination antiretroviral therapy (cART) with suppressed HIV RNA. We hypothesized that T-cell dysfunction would be increased in these patients.
METHODS: In the Danish HIV Cohort Study, we identified HIV-1-infected patients initiating cART with a CD4 cell count <100 cells per microliter, followed by HIV RNA <50 copies per milliliter for 3 years. Patients with a CD4 count <200 cells per microliter after 3 years were identified as cases; 42 patients with a CD4 count > or = 200 cells per microliter were selected as controls. Six-color flow cytometry was performed on whole blood. Cytokine levels in supernatants from whole blood stimulations were assessed.
RESULTS: The case and control groups comprised 18 and 35 patients, respectively. Cases were older than controls (median: 54/46 years). The fraction of CD28+ cells was decreased among cases in the CD4+ and CD8+ T-cell subsets (P = 0.0014/P = 0.0349) and in the corresponding naive subsets (P = 0.0011/P , 0.0001). Cases had higher expression of human leukocyte antigen (HLA)-DR on naive CD4 and CD8 T cells (P = 0.0007/P = 0.0028). The production of interleukin (IL)-10 and IL-2 to phytohemagglutinin was decreased in cases (P < 0.0001/P = 0.019).
CONCLUSIONS: Patients with impaired CD4 recovery shared a dysregulated T-cell phenotype with low CD28, high HLA-DR expression, and low IL-2 and IL-10 production.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20048679     DOI: 10.1097/QAI.0b013e3181ca3f7c

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  11 in total

Review 1.  HIV-1/mycobacterium tuberculosis coinfection immunology: how does HIV-1 exacerbate tuberculosis?

Authors:  Collin R Diedrich; Joanne L Flynn
Journal:  Infect Immun       Date:  2011-01-18       Impact factor: 3.441

2.  Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes.

Authors:  Liguo Niu; James M Termini; Saravana K Kanagavelu; Sachin Gupta; Morgane M Rolland; Viraj Kulkarni; George N Pavlakis; Barbara K Felber; James I Mullins; Margaret A Fischl; Geoffrey W Stone
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

3.  Association between discordant immunological response to highly active anti-retroviral therapy, regulatory T cell percentage, immune cell activation and very low-level viraemia in HIV-infected patients.

Authors:  J Saison; T Ferry; J Demaret; D Maucort Boulch; F Venet; T Perpoint; F Ader; V Icard; C Chidiac; G Monneret
Journal:  Clin Exp Immunol       Date:  2014-06       Impact factor: 4.330

4.  Impact of highly active antiretroviral therapy initiation on CD4(+) T-cell repopulation in duodenal and rectal mucosa.

Authors:  Timothy L Hayes; David M Asmuth; J William Critchfield; Thomas H Knight; Bridget E McLaughlin; Tammy Yotter; Delandy H McConnell; Juan Carlos Garcia; Richard B Pollard; Barbara L Shacklett
Journal:  AIDS       Date:  2013-03-27       Impact factor: 4.177

Review 5.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

6.  Increased Regulatory T-Cell Percentage Contributes to Poor CD4(+) Lymphocytes Recovery: A 2-Year Prospective Study After Introduction of Antiretroviral Therapy.

Authors:  Julien Saison; Delphine Maucort Boulch; Christian Chidiac; Julie Demaret; Christophe Malcus; Laurent Cotte; Francoise Poitevin-Later; Patrick Miailhes; Fabienne Venet; Mary Anne Trabaud; Guillaume Monneret; Tristan Ferry
Journal:  Open Forum Infect Dis       Date:  2015-05-01       Impact factor: 3.835

7.  Systemic Cytokine Levels Do Not Predict CD4(+) T-Cell Recovery After Suppressive Combination Antiretroviral Therapy in Chronic Human Immunodeficiency Virus Infection.

Authors:  Philip J Norris; Jinbing Zhang; Andrew Worlock; Sangeetha V Nair; Kathryn Anastos; Howard L Minkoff; Maria C Villacres; Mary Young; Ruth M Greenblatt; Seema Desai; Alan L Landay; Stephen J Gange; C Thomas Nugent; Elizabeth T Golub; Sheila M Keating
Journal:  Open Forum Infect Dis       Date:  2016-02-08       Impact factor: 3.835

8.  Preserved immune functionality and high CMV-specific T-cell responses in HIV-infected individuals with poor CD4+ T-cell immune recovery.

Authors:  Elisabet Gómez-Mora; Elisabet García; Victor Urrea; Marta Massanella; Jordi Puig; Eugenia Negredo; Bonaventura Clotet; Julià Blanco; Cecilia Cabrera
Journal:  Sci Rep       Date:  2017-09-15       Impact factor: 4.379

Review 9.  Role of Kupffer Cells in Driving Hepatic Inflammation and Fibrosis in HIV Infection.

Authors:  Lumin Zhang; Meena B Bansal
Journal:  Front Immunol       Date:  2020-06-16       Impact factor: 7.561

10.  Determinants of suboptimal CD4+ T cell recovery after antiretroviral therapy initiation in a prospective cohort of acute HIV-1 infection.

Authors:  Ryan Handoko; Donn J Colby; Eugène Kroon; Carlo Sacdalan; Mark de Souza; Suteeraporn Pinyakorn; Peeriya Prueksakaew; Chutharat Munkong; Sasiwimol Ubolyam; Siriwat Akapirat; Jennifer Chiarella; Shelly Krebs; Irini Sereti; Victor Valcour; Robert Paul; Nelson L Michael; Nittaya Phanuphak; Jintanat Ananworanich; Serena Spudich
Journal:  J Int AIDS Soc       Date:  2020-09       Impact factor: 5.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.